Introduction
Th e human cornea is the main refractive surface focusing light into the eye, so its transparency is critical for vision. Irreversible transparency loss from injury or disease can, therefore, lead to blindness. Globally, approximately 4.9 million individuals have bilateral cornea blindness, while 23 million are unilaterally cornea blind.
1 Donor tissue transplantation is the only widely accepted treatment but the need for donor corneas exceeds the supply and the gap only increases as the population ages.
Recent advances in corneal transplantation techniques with a shift from penetrating to safer lamellar procedures and wide application of limbal epithelial stem cell transplantation, have resulted in improved outcomes, and have expanded the number of cases of corneal blindness that can now be treated successfully. 2 However, patients with severe pathologies (e.g., chemical burns, previously rejected graft s, autoimmune disease, and infections) still have a high risk of rejection and failure, oft en needing multiple surgeries. [3] [4] [5] [6] [7] [8] Corneal prostheses are available, but they remain mainly for end-stage disease and even if implanted as primary procedure they oft en are accompanied by visionthreatening complications, 1, 9 leaving an unmet need for a de novo solution for high-risk patients.
In Ukraine, as in many countries, there is a severe shortage of donor corneas. Th e annual need in 2010 was 4000 graft s, but only 511 corneal transplantations were performed due to the lack of donated tissues. Fift y-four percent of these transplantations were performed for tectonic purposes due to the increasing number of infections and injuries. 10 To solve the problems of lack of donor tissues as well as the high risk of rejection of allograft ed corneas, we had developed corneal implants made from interpenetrating networks of cross-linked recombinant human collagen type III (RHCIII) and 2-methacryloyloxyethyl phosphorylcholine (MPC), a synthetic phospholipid 11 ( Figure 1 ). MPC-polymer has antifouling properties and has been FDA approved as a polymer coating in vascular stents. 12 Here, it was incorporated into RHCIII to prevent neovascularization.
We previously tested implants comprising RHCIII alone as substitutes for donor corneas in a Phase 1 clinical study, where they promoted good tissue integration with stable regeneration of corneal epithelium, stroma and nerves, restoration of corneal refl ex better than allograft ( p = 0.04), maintenance of transparency in cornea and no tissue rejection reported on 4-year followup, in the absence of long-term steroid immunosuppression beyond Week 7 postimplantation, in patients with keratoconus or central scarring, i.e., low-risk patients, 13 Like donor corneas, however, RHCIII only implants became neovascularized when graft ed into a model of severe pathology, the alkali-burned rabbit cornea.
14 Incorporation of MPC into RHCIII, on the other hand, yielded implants that repelled blood vessels 14 while allowing regeneration. 15, 16 Here, we report our initial experience with RHCIII-MPC implants into three patients for whom donor cornea graft ing carried a high risk of rejection. Th e primary aim of this early investigation was to assess the safety of such an approach. Th e secondary aim was to test the feasibility of restoring the integrity of the cornea. 11 by anterior lamellar corneal transplantation.
Bioengineered Corneas Grafted as
Patient 1, an 80-year-old male, suff ered an alkali burn to his right eye resulting in a persistent corneal ulcer resistant to conventional medical treatment and bandage contact lens wear. He suff ered from pain, tearing, and photophobia due to the inability of the corneal epithelium to stably adhere to the underlying damaged and vascularized stroma. Patient 1's best corrected visual acuity (BCVA) was 6/600, i.e., near blindness. Patient 2 was a 72-year-old female with a previously rejected penetrating human cornea graft in her left eye, which was combined with cataract extraction and intraocular lens (IOL) implantation. She suff ered from corneal ulceration, which was unresponsive to medical treatment and bandage contact lens wear, and had the same symptoms as Patient 1, with only light perception, i.e., eff ectively blind. She had a very dense stromal opacifi cation in the ulcerated area. Patient 3 was a 52-year-old male who suff ered from recurrent corneal erosions following an acid burn. Th e erosions were resistant both to medical treatment and bandage contact lens wear. Th e underlying stroma was scarred and vascularized. His symptoms were similar to those of the other two patients. During the chronic stage of the burn, he received excimer laser phototherapeutic keratectomy and a human amniotic membrane (HAM) graft for ocular surface healing. He has also had a cataract phacoemulsifi cation and was implanted with an IOL one year aft er the injury. His BCVA was 6/600, i.e., near blindness.
All three patients needed surgery to treat the ulceration, restore corneal integrity, alleviate the associated pain and discomfort, and to improve vision. Based on literature review all were considered high-risk patients for limbal epithelial graft rejection as well as penetrating or lamellar cornea graft rejection and failure. Each patient's pathologic cornea was initially cut with a 4-5-mmdiameter trephine (depending on lesion diameter) to remove the lesioned area with a small epithelialized margin around it. Th e incision was then deepened with a diamond knife set to a depth of 250 or 350 μ m (depending on lesion depth). Manual lamellar dissection was then used to remove the pathologic corneal tissue. A trephine of the same diameter was used to cut the biosynthetic implant of corresponding thickness. Once in place, the implant was anchored with three to four overlying 10-0 nylon mattress sutures to avoid puncturing the implant material. Aft er surgery, they received a topical antibiotic (moxifl oxacin hydrochloride 0.5%, s.a. Alcon-Couvreur n.v., Puurs, Belgium), a short-term mydriatic (cyclopentolate 1%, Sentiss Pharma Pvt. Ltd., Gurgaon, India) and a nonsteroidal anti-infl ammatory drug (indomethacin 0.1%, Bausch + Lomb GmbH, Dr. Gerhard Mann chem.-pharm. Fabrik GmbH, Berlin, Germany) for 2 weeks. Th is was followed by a topical antiseptic (chlorhexidine bigluconate 0.02%, Farmacia, Lugansk, Ukraine) and a steroid (dexamethasone 0.1%, s.a. AlconCouvreur n.v., Puurs, Belgium) for 4 weeks. Th e patients wore 14-mm bandage contact lenses containing 36% water (Bausch & Lomb PureVision) until epithelial regeneration was complete.
Patients were assessed at 1, 3, 6, 9, and 12 months postoperatively or as determined required by the physician. Th e patients' observations of their own pain, irritation and photophobia were recorded. Clinical assessment performed included slit-lamp biomicroscopy to check for signs of infl ammation or infection, a fl uorescein staining test to confi rm epithelial integrity, corneal surface sensitivity assessment (Cochet-Bonnet esthesiometer, Luneau Ophthalmologie, France), best corrected visual acuity measurement, transpalpebral tonometry to measure intraocular pressure without damaging the epithelium (Diaton, Ryazan State Instrument-Making Enterprise, Russia), ultrasound pachymetry (SP-100, Tomey, Japan) and in vivo confocal microscopy (ConfoScan4, Nidek, Japan). Table 1 shows the optical and physical properties of the RHCIII-MPC implants. All implants had similar optical properties to healthy human corneas. While they were mechanically weaker than human donor corneas, they were nevertheless robust enough to withstand the handling and graft ing procedure.
Results
Epithelial coverage of the initially cell-free implants took on average 6 weeks ( Table 2 , Figure 2 ). All three implants remained free of neovascularization or epithelial erosions over the 9-12 months postoperation follow-up period. However, conjunctival epithelium invaded the implant surface in Patient 3, due to limbal stem cell defi ciency ( Figure 2 ). Th ere was no stromal edema, no prolonged infl ammation nor any infection in any patient. Touch sensitivity increased aft er surgery in all patients although not to the level of normal human corneas ( Figure 3 ). Aft er the mild deturgescence of the edema that always accompanies corneal ulceration, the corneal thickness remained stable throughout the follow-ups. Intraocular pressure remained within normal ranges. Tear production was comparable to that in the nonoperated contralateral eyes. Signs of punctate precipitate and haze appeared at the posterior surface of the implant during the third postoperative week in all cases, but resolved aft er two weeks of treatment with topical steroids. Visual acuity improved in Patients 1 and 2 from near blindness (6/600 and LP) to moderate (6/38) and severe (6/75) vision loss, respectively, allowing for restricted function with enhancing aids. Patient 3, who had conjunctivalization of corneal surface, showed no change in vision but no longer had recurrent painful erosions seen preoperatively, suggesting that RHCIII-MPC implants could stabilize the corneal surface pending further treatment, e.g., limbal stem cell graft ing to improve vision. Implants remained stably incorporated without immunosuppression beyond the 6-week course of prophylactic anti-infl ammatory medication.
In vivo confocal microscopy of the regenerated neo-cornea of Patient 1 showed a regenerated epithelium ( Figure 4 A) , which resembled that of a healthy cornea ( Figure 4 B) . Stromal cells were not clearly seen due to corneal haze, but they appear to have started populating the initially cell-free implant ( Figure 4 C) but have not reached the steady state seen in a healthy cornea ( Figure 4 D) . Th e patient's preserved endothelium remained intact ( Figure 4 
E).

Discussion
In many countries, such as Ukraine, China, South East Asia, and India, corneal blindness is a huge problem. In addition to the severe shortage in donated corneas, 10 many patients suff er from severe pathologies that have a high risk of graft rejection or failure. Poor outcomes of corneal transplantation are likely due to graft rejection and stem cell defi ciency.
Graft rejection is directed at allogenic cells from donor human corneas. 18 Th is is circumvented by cell-free RHCIII-based corneal implants. Th e RHCIII replaces the largely collagenous stroma of the native cornea allowing for repopulation by endogenous host corneal cells, as we had previously reported in low-risk patients. 13 We have previously shown that the RHCIII-MPC implants are composed of lamellae-like layers that are interconnected with fi berlike structures that crudely mimics the structure of the human cornea.
11 Furthermore, the coeffi cients of glucose and albumin diff usion through these hydrogels were comparable to that of the human cornea. 15 Additionally, MPC polymer has reported antiinfl ammatory properties, 19, 20 possibly accounting for the capacity of RHCIII-MPC implants to quiesce the immunopathologic corneas, allowing stable restoration of the ocular surface.
Corneal epithelial limbal stem cell transplantation, which is available in large urban centers in the developed world, is too cost prohibitive for the healthcare systems in many countries such as Ukraine, as it requires specialized, certifi ed clean rooms and staffi ng to expand the cultures, plus time for harvesting through cultivation of cells. In addition, where the damage to the cornea extends below the epithelium, the patients require a subsequent donor graft . In this case, a graft ed RHCIII-MPC implant can allow for healing of the epithelium and stroma, providing relief from pain and discomfort for patients and allowing for a future limbal epithelial graft as the second step in the treatment. In this initial observational study, small graft s of 4-5 mm were used to replace the lesioned area with a minimal margin of healthy tissue. Th e rationale for this was patient safety, i.e., in case of a serious adverse device eff ect, the implant can be removed and replaced with a larger human donor cornea graft by deep lamellar keratoplasty, the current conventional treatment.
Following corneal wounding, overexpression of unaligned, mainly type III collagen occurs to form a scar. 21 Bridging the wound gap with RHCIII-MPC implants that have a regular lamellar structure, 11 however, appears to provide a template for more controlled in-growth of stromal cells that in turn provides for an optically clear regenerated cornea. Nonetheless, in patients with limbal epithelial stem cell defi ciency, transplantation with corneal epithelial stem cells in conjunction with an implant will be needed to prevent conjunctival in-growth that decreases optical clarity.
We have shown that under conditions that render standard of care suboptimal, e.g., Ukraine due to its on-going crisis, making the situation approach that in much of the developing world, 22 RHCIII implants have the potential to overcome the cornea supply shortage in various regions in the world, and avoid social and religious stigma some may have with allograft corneas. Furthermore, RHCIII-MPC implants may be an alternative to donor corneas and possibly a superior substitute in high-risk cases for restoring corneal integrity.
Conclusion
Despite of the limitations of this preliminary case study such as the very small sample population and relatively short followup of 9-12 months, our initial results nevertheless suggest that bioengineered RHCIII-MPC implants may potentially be more effi cacious alternatives to donor tissues in repairing corneas with severe pathologies. Th erefore, further clinical evaluation in form of a clinical study with high-risk patients is merited to determine their safety and full potential as alternatives to donor human cornea transplantation.
